<DOC>
	<DOCNO>NCT01799889</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability , pharmacodynamics entospletinib . Participants follow relapsed refractory hematologic malignancy enrol study : relapsed refractory chronic lymphocytic leukemia ( CLL ) , mantle cell lymphoma ( MCL ) , diffuse large B-cell lymphoma ( DLBCL ) , follicular lymphoma ( FL ) , non-FL indolent non-Hodgkin lymphoma ( iNHL ; include lymphoplasmacytoid lymphoma/ Waldenström macroglobulinemia [ LPL/WM ] , small lymphocytic lymphoma [ SLL ] , marginal zone lymphoma [ MZL ] ) .</brief_summary>
	<brief_title>Entospletinib Adults With Relapsed Refractory Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Key Diagnosis Bcell iNHL , DLBCL , MCL , CLL document medical record histology base criterion establish World Health Organization For institution Phase 3 Phase 4 protocol study idelalisib ( Zydelig® ) ; individual malignancy study protocol must fail screen respective idelalisib protocol Prior treatment lymphoid malignancy require treatment progressive disease Presence radiographically measurable lymphadenopathy extranodal lymphoid malignancy All acute toxic effect prior antitumor therapy resolve Grade ≤ 1 start study drug Karnofsky performance status ≥ 60 Life expectancy least 3 month Key Known histological transformation iNHL CLL aggressive form nonHodgkin lymphoma ( ie , Richter transformation ) except CLL patient enrol Bcell receptor ( BCR ) previously treat cohort Known active central nervous system leptomeningeal lymphoma Presence know intermediate highgrade myelodysplastic syndrome Evidence ongoing systemic bacterial , fungal , viral infection time start study drug Ongoing liver injury Ongoing recent hepatic encephalopathy Ongoing druginduced pneumonitis Ongoing inflammatory bowel disease Ongoing alcohol drug addiction Pregnancy breastfeed History prior allogeneic bone marrow progenitor cell solid organ transplantation Ongoing immunosuppressive therapy Concurrent participation investigational drug trial therapeutic intent NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>GS-US-339-0102</keyword>
	<keyword>SYK inhibitor</keyword>
	<keyword>GS-9973</keyword>
	<keyword>entospletinib</keyword>
	<keyword>CLL</keyword>
	<keyword>leukemia</keyword>
	<keyword>lymphoma</keyword>
	<keyword>MCL</keyword>
	<keyword>DLBCL</keyword>
	<keyword>iNHL</keyword>
	<keyword>FL</keyword>
	<keyword>MZL</keyword>
	<keyword>LPL</keyword>
	<keyword>SLL</keyword>
	<keyword>WM</keyword>
	<keyword>Waldenström 's macroglobulinemia</keyword>
</DOC>